Navigation Links
Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia
Date:12/8/2009

positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST) and the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.

Furthermore, imatinib is approved for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy, adult patients with relapsed or refractory Ph+ ALL as monotherapy, adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements, adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR alpha rearrangement and the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

    For imatinib summary of product characteristics, please see:
    http://emc.medicines.org.uk/document.aspx?documentId=15014

    References

    (1) Saglio G, Kim DW, Issaragrisil S, Philipp le Coutre, et al.
        Nilotinib Demonstrates Superior Efficacy Compared with Imatinib in
        Patients with Newly Diagnosed Chronic Myeloid Leukaemia in Chronic
        Phase: Results from the International Randomized Phase III ENESTnd
        Trial. American Society of Hematology 2009. Abstract number LBA-1

    (2) NICE Guidance on the use of imatinib for chronic myeloid leukaemia
        - Technology Appraisal 70. October 2003

    (3) Faderl S; Talpaz M; Estrov Z; O'Brien S; Kurzrock R; Kantarjian HM.
        The biology of chronic myeloid leukemia. N Engl J Med. 341:164-72,
        1999.

    (4) National Cancer Institute. Ge
'/>"/>
SOURCE  Novartis Oncology
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... YORK , May 21, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Regulatory and Reimbursement Scenario for Medical Devices ... http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging   Changing ... in the US Market   ...
(Date:5/21/2013)... MONROVIA, Calif. , May 21, 2013 ... leading developer, manufacturer and marketer of minimally invasive ophthalmic ... upcoming investor conferences to review the Company,s recent financial ... STAAR Surgical will present at the 38 ... Boston at the Westin Waterfront ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4STAAR Surgical To Present At Upcoming Investor Conferences 2
... Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today ... that once-daily Victoza ® in combination with metformin produced sustained and significantly ... ® plus metformin at 52 weeks. , ... Key findings from the study include: , ...
... JACKSONVILLE, Fla. , June 28 ... of its SurgiSteer™ laparoscopic instruments.  Developed from licensed ... will exploit single port laparoscopic surgery with its ... and Endo Scissors, available in both free and ...
Cached Medicine Technology:New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 2New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 3New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 4New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 5New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 6New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 7Steerable Technologix LLC Announces Release of SurgiSteer Laparoscopic Instruments 2
(Date:5/21/2013)... Dallas-based TopMD™ Skin Care today announced results of ... of their flagship product, CLn® BodyWash for ... in the May/June 2013 issue of Pediatric Dermatology ... Cleanser Shows Clinical Response and Excellent Acceptability in the ... consistent use of the product by 18 pediatric patients ...
(Date:5/21/2013)... Dimensional Insight, a developer of business intelligence ... Health System, a 275-bed hospital based in Cumberland, ... help it analyze its data more quickly. Western Maryland ... through Dimensional Insight’s recently announced partnership with Premier ... has massive amounts of data in disparate systems, such ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Romio ... people with trusted services & businesses, announced today that ... Emergency Medical Care. , Emergency Medical Care is located ... services 24 hours a day. The guarantee of ... is a promising resource for the neighborhood and a ...
(Date:5/21/2013)... Reporter , , MONDAY, May 20 (HealthDay News) -- Young ... a higher risk of getting into car crashes, but ... missed sleep on weekends puts them in even greater ... is another challenge to adolescents that comes with lack ... founder of the Center for Injury Research and Prevention ...
(Date:5/21/2013)... TUESDAY, May 21 (HealthDay News) -- Racial disparities exist ... hospitals in the United States, according to a large ... undergo surgery as part of their initial treatment, researchers ... whites to have surgery in the early stages of ... for stage 1 and stage 2 disease than white ...
Breaking Medicine News(10 mins):Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 2Health News:Peer-Reviewed Article Shows CLn® BodyWash an Effective Solution for Children with Eczema 3Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 2Health News:Dimensional Insight Announces Western Maryland Health System as First Customer Through Premier Healthcare Alliance 3Health News:Romio Announces Mini Video Series Featuring Local Business Emergency Medical Care 2Health News:Weekend 'Catch-Up' Sleep May Cut Young Drivers' Crash Risk 2Health News:Racial Disparities Seen in U.S. Lung Cancer Treatment 2
... NY) For the third time in four months, the ... National Institutes of Health (NIH) has awarded Albert Einstein College ... helping people infected with multidrug-resistant tuberculosis (MDR-TB). Taken ... latest awardee Neel Gandhi, M.D. , assistant professor ...
... July 27, 2010 Researchers at UT Southwestern Medical ... doses of corticosteroids given repeatedly over several weeks may ... affects more than 1 million people in the U.S. ... sometimes use illegally to bulk up muscle, corticosteroids are ...
... By Madonna Behen HealthDay Reporter , MONDAY, July ... Administration has required that all epilepsy drugs bear a warning ... doctors report that only certain medications may increase the risk ... the findings and say the paper raises more questions than ...
... such as everolimus that target the protein mTOR are used ... respond to the treatment. A team of researchers, led by ... has now identified a way to help predict which patients ... that human cancer cells with mutations in the PIK3CA gene ...
... major research company affiliated with the University of Colorado ... the University of Colorado,s Anschutz Medical Campus to more ... laboratory to the patient. CPC, formally known as the ... Incorporated building across the street from the campus on ...
... Society for Radiation Oncology (ASTRO) has named N. Reed ... diagnostic radiology, as its 2010 Honorary Member, which is ... researchers and leaders in disciplines other than radiation oncology, ... with this honor during the Awards Ceremony at ASTRO,s ...
Cached Medicine News:Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 2Health News:Major funding awarded to improve treatment of drug-resistant tuberculosis and HIV co-infection 3Health News:Researchers uncover biological rationale for why intensive lupus treatment works 2Health News:Researchers uncover biological rationale for why intensive lupus treatment works 3Health News:Not All Epilepsy Drugs Raise Suicide Risk: Study 2Health News:Not All Epilepsy Drugs Raise Suicide Risk: Study 3Health News:University of Colorado joins forces with major research affiliate 2Health News:ASTRO names radiologist, ABR president Society's 2010 Honorary Member 2
... is a state-of-the-art hair reduction and ... specially designed for use within a ... features and economy in a single ... treatment of unwanted hair, photo rejuvenation ...
... perfect mix of powerful, versatile, and innovative ... Palomar StarLux® Pulsed Light and Laser System.,With ... compact base unit so theres no ... treatments., You can choose among Laser, Intense ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
... Pump provides optimum flow rate ... Operates on any voltage worldwide. ... safety Interlock and easy load ... Double Spike Tubing, Dual Pneumatic ...
Medicine Products: